Hamilton Thomas Edward 4

What Happened

• Thomas E. Hamilton, a director of Larimar Therapeutics, was granted 55,150 derivative securities on May 19, 2026. The reported acquisition price is $0.00 and the transaction is recorded as a grant/award (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-19; filing date: 2026-05-20 (timely).
• Amount granted: 55,150 derivative shares at $0.00 reported price; total cash consideration reported = $0.
• Vesting: Per footnote F1, the awards vest on the earlier of (a) May 19, 2027 or (b) the date of the company’s next annual meeting, subject to Hamilton’s continued service on the board.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Filing timeliness: Reported the day after the grant; not indicated as late.

Context

• This is a grant of derivative securities (award) to a director — a routine form of equity compensation for board service. The filing does not indicate an immediate sale or exercise; it simply records the award and its vesting condition. As with most director grants, this is compensation-related and does not by itself indicate the director’s market view.